# FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

> **NCT05755048** · PHASE3 · UNKNOWN · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 314 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
- **BIOLOGICAL:** Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

## Key facts

- **NCT ID:** NCT05755048
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-28
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-01-31
- **Target enrollment:** 314 (ESTIMATED)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755048, "FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05755048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*